Mylan Completes Acquisition of Generics Business of Merck KGaA

    PITTSBURGH, Oct. 2 /CNW/ -- Mylan (NYSE:   MYL) announced today that it has
completed its acquisition of Merck KGaA's generics business ("Merck Generics")
to become one of the largest quality generics and specialty pharmaceuticals
companies in the world. Mylan and Merck KGaA initially announced the signing
of a definitive agreement under which Mylan would acquire Merck Generics for
EUR 4.9 billion ($6.8 billion) in an all-cash transaction on May 12, 2007.
    Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer said,
"The new Mylan now has all of the critical attributes we need to ensure future
success and deliver powerful growth. We have enhanced scale and stability, a
truly global reach, vertical and horizontal integration, and breadth and depth
in our management team. Most importantly, we have a common purpose and
dedication to executing on our strategy and delivering superior shareholder
    The new Mylan is the third largest generic company worldwide, employs
more than 11,000 people and has a global presence in more than 90 countries.
Mylan's broad product offering now includes more than 570 products and the
world's second largest portfolio of active pharmaceutical ingredients (APIs)
with 126 U.S. drug master files (DMFs). Mylan has a powerful global pipeline
with more than 255 applications or dossiers pending regulatory approval. The
new Mylan will benefit from substantial operational efficiencies and economies
of scale from increased sales volumes and its vertically and horizontally
integrated platform. Dey, Mylan's specialty pharmaceuticals business, brings
additional exciting and diversified opportunities through its existing
strengths in the respiratory arena.
    Mr. Coury continued, "The scale of the new Mylan is evident in every area
of our business: we have scale in our geographic reach, scale in R&D, scale in
manufacturing, scale in API, scale in our combined product portfolio, and
scale in our global commercial footprint. We will leverage this scale to drive
operational efficiencies and extract synergies from our combined company,
while attracting exciting new opportunities. We have also created an extremely
well-balanced and diversified company, with significantly reduced risks
related to any one particular market or product. Importantly, we will also
ensure that we retain the qualities that customers around the world have come
to expect from both Mylan and Merck Generics.
    "The Merck Generics business is even stronger than we expected and,
through the integration planning, we have confirmed that we truly share a
common culture and values centered on quality, integrity, reliability and
service. I am thrilled to welcome Merck Generics nearly 5,000 employees to the
new and expanded Mylan family. After months of careful preparation, we have
hit the ground running with the integration of our businesses and I am
delighted that we will be operating as a single, integrated company from day
    Mylan also announced today that the company will change its name from
Mylan Laboratories Inc. to Mylan Inc. to better reflect the broader scope of
its business. The Company also confirmed that it has changed its financial
year to begin reporting on a calendar year basis.

    Investor Day on October 3

    Mylan will provide more details on its go-forward strategy and its
financial outlook during its Investor Day in New York, New York, on October 3,
2007. The agenda will include presentations delivered by each of Mylan's
global regional heads and several members of Mylan's senior management team.
The presentations will be available live via webcast beginning at 8:30 a.m.
    To access the live webcast, go to Mylan's Web site at and
click on the webcast icon at least 15 minutes before the event is scheduled to
begin to register and download or install any necessary audio software. A
replay of the webcast will be available on until November 2,

    About Mylan

    Mylan Inc. is one of the world's leading quality generic and specialty
pharmaceutical companies. The Company offers one of the industry's broadest
and highest quality product portfolios, a robust product pipeline and a global
commercial footprint through operations in more than 90 countries. Through its
controlling interest in Matrix Laboratories Limited, Mylan has direct access
to one of the largest active pharmaceutical ingredient (API) manufacturers in
the world. Dey L.P., Mylan's fully integrated specialty business, provides the
Company with innovative and diversified opportunities in the respiratory and
allergy therapeutic areas.

    For more information about Mylan, please visit

    Forward-Looking Statements

    This press release contains statements that constitute "forward-looking
statements", including with regard to Mylan's future success, the anticipated
benefits of operational efficiencies and leverage, and expected product and
other opportunities. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Because
such statements inherently involve risks and uncertainties, actual future
results may differ materially from those expressed or implied by such forward-
looking statements. Factors that could cause or contribute to such differences
include, but are not limited to: challenges and costs relating to integration
of the two businesses; the effect of any changes in customer and supplier
relationships and customer purchasing patterns; the impact and effects of
legal or regulatory proceedings, actions or changes; general market perception
of the transaction; the ability to attract and retain key personnel; changes
in economic and financial conditions of the Company's business; uncertainties
and matters beyond the control of management; and the other risks detailed in
the Form 10-Q for the quarter ended June 30, 2007 and the other periodic
reports filed by the Company with the Securities and Exchange Commission. The
Company undertakes no obligation to update these statements for revisions or
changes after the date of this release.

For further information:

For further information: Kris King, Mylan Inc., +1-724-514-1800; Nina 
Devlin or Cindy Leggett-Flynn, Brunswick Group, +1-212-333-3810, for Mylan
Inc. Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890